Skip to main content
. 2019 Nov 10;20(22):5616. doi: 10.3390/ijms20225616

Table 2.

Clinical Trials Involving CML Patients Treated either with Investigational Molecules in Combination with TKIs or Alone.

Scheme
Number
Treatment 1 Treatment 2 Pathway Investigation Phase Identifier First Posted Status
1 Imatinib
Nilotinib
Dasatinib
Asciminib BCR-ABL1 allosteric inhibitor Frontline combination in CP- CML II NCT03906292 2019 Recruiting
2 none Asciminib BCR-ABL1 allosteric inhibitor Efficacy of ABL001 versus Bosutinib in CP-CML patients previously treated with TKIs III NCT03106779 2017 Recruiting
3 Dasatinib Asciminib BCR-ABL1 allosteric inhibitor Combination in CML in lymphoid blast crisis I NCT03595917 2018 Recruiting
4 Imatinib Asciminib BCR-ABL1 allosteric inhibitor Efficacy and safety of combination in patients with CP-CML II NCT03578367 2018 Recruiting
5 Imatinib
Nilotinib
Dasatinib
Asciminib BCR-ABL1 allosteric inhibitor Oral ABL001 in CML Patients I NCT02081378 2014 Recruiting
6 Imatinib Cytarabine DNA synthesis inhibitor Combination in patients with CML II NCT00022490 2003 Terminated
7 Imatinib Cytarabine DNA synthesis inhibitor Combination in patients with CML I/II NCT00015834 2003 Completed
8 Dasatinib SAHA
(Vorinostat)
HDAC inhibitor Combination in treating patients with accelerated phase or BP- CML I NCT00816283 2009 Completed
9 Imatinib Panobinostat
(LBH589)
HDAC inhibitor Safety and tolerability of LBH589 combined with imatinib in CML patients in MCR I NCT00686218 2008 Completed
10 Imatinib Decitabine DNA methyltransferase inhibitor Combination in patients with CML II NCT00054431 2003 Completed
11 Dasatinib Venetoclax BCL2 inhibitor Combination in treating patients with BCR-ABL1 positive early chronic phase II NCT02689440 2016 Recruiting
12 Ponatinib Venetoclax Dexamethasone BCL2 inhibitor
Anti-inflammatory
Triple combination in BCR-ABL positive relapsed CML I/II NCT03576547 2018 Recruiting
13 Imatinib Oblimersen bcl-2 antisense oligodeoxynucleotide Oblimersen and Imatinib in treating patients with CML II NCT00049192 2003 Completed
14 Imatinib Hydroxychloroquine Autophagy inhibitor Effectiveness of combination on BCR/ABL levels in CML patients in MCR II NCT01227135 2010 Unknown
15 Imatinib Everolimus (RAD001) mTOR inhibitor Combination in patients in CP-CML who are not in CCR after previous Imatinib I/II NCT00093639 2004 Completed
16 Imatinib Temsirolimus mTOR inhibitor Temsirolimus and Imatinib in treating patients with CML I NCT00101088 2005 Terminated
17 Dasatinib PF04449913
(Glasdegib)
Smo antagonist
HH inhibition
Study of PF-04449913 in select hematologic malignancies I NCT00953758 2009 Completed
18 Imatinib Interferon-α Immunomodulatory effect INF-α and Imatinib in CML patients II NCT00045422 2003 Completed
19 Imatinib Pioglitazone PPARγ agonist
STAT5 inhibition
Combination in patients with relapsed CML II NCT02767063 2016 Terminated
20 Imatinib Pioglitazone PPARγ agonist
STAT5 inhibition
Efficiency of combination to treat CML II NCT02687425 2016 Unknown
21 TKIs Pioglitazone PPARγ agonist
STAT5 inhibition
Pioglitazone and TKI in patients with relapsed CML II NCT02730195 2019 Terminated
22 Dasatinib Cyclosporine IL-2 inhibitor Combination in patients with CML refractory or intolerant to imatinib I NCT01426334 2011 Terminated
23 Pioglitazone Avelumab (Anti-PD-L1) PPARγ agonist
STAT5 inhibition PD-1/PD-L1 inhibition
Therapies in combination or sequentially with TKIs in CP-CML patients in CCR (ACTIW) I/II NCT02767063 2016 Recruiting
24 Imatinib
Nilotinib
Dasatinib
Pembrolizumab (Anti-PD-1) PD-1/PD-L1 inhibition Pembrolizumab and TKIs in CML patients with persistently detectable MRD II NCT03516279 2018 Recruiting
25 Dasatinib
Nilotinib
Ruxolitinib JAK1/2 selective inhibitor Ruxolitinib phosphate and Dasatinib or Nilotinib in treating CML patients II NCT03654768 2018 Recruiting
26 Nilotinib Ruxolitinib JAK1/2 selective inhibitor Ruxolitinib in treating participants with CML with MRD after TKIs I/II NCT01751425 2012 Active, not recruiting
27 Nilotinib Ruxolitinib JAK1/2 selective inhibitor Nilotinib/Ruxolitinb therapy for TKI resistant Ph-Leukemia I//II NCT01914484 2013 Unknown
28 Nilotinib Ruxolitinib JAK1/2 selective inhibitor Combination in CP-CML Patients I NCT01702064 2012 Completed
29 Nilotinib Peginterferon α2b Immunomodulatory effect Evaluation of TKI and INF-α III NCT01657604 2012 Active, not recruiting
30 Imatinib
Nilotinib
Peginterferon α2b Immunomodulatory effect Imatinib or Nilotinib with Pegylated Interferon-α2b in CML II NCT00573378 2007 Withdrawn
31 Dasatinib Peginterferon α2b Immunomodulatory effect Safety and efficacy of combination in newly diagnosed CML (NordCML007) II NCT01725204 2012 Completed
32 Bosutinib Ropeginterferon Immunomodulatory effect Long-acting low dose Ropeginterferon for CML treated with Bosutinib from diagnosis II NCT03831776 2019 Recruiting
33 Nilotinib Sonidegib (LDE225) Smo antagonist
HH inhibition
Combination in CML patients who developed resistance to prior therapy I NCT01456676 2011 Completed
34 Dasatinib BMS-833923 Smo antagonist
HH inhibition
Combination therapy in CML I/II NCT01218477 2010 Completed
35 Dasatinib BMS833923 Smo antagonist
HH inhibition
Dasatinib combo with Smo antagonist II NCT01357655 2011 Terminated
36 Dasatinib PF04449913 Smo antagonist
HH inhibition
Study in select hematologic malignancies I NCT00953758 2009 Completed
37 Imatinib Zarnestra Farnesyltransferase inhibitor Zarnestra and Gleevec in CP- CML I NCT00040105 2002 Completed
38 Imatinib Lonafarnib Farnesyltransferase inhibitor Lonafarnib and Gleevec in CML I NCT00047502 2002 Completed
39 none Sorafenib (BAY43-9006) Raf/VEGFR/PDGFR inhibitor Raf kinase inhibitor BAY 43-9006 in CML patients resistant to Gleevec II NCT00661180 2008 Completed
40 Imatinib Vatalanib (PTK 787) VEGFR inhibitor Combination in patients with BP-CML I/II NCT00088231 2004 Completed
41 Dasatinib BP1001 Grb2 inhibitor Combination of liposomal Grb2 antisense oligonucleotide with Dasatinib in CML patients I/II NCT02923986 2016 Recruiting
42 none MK0457 Aurora kinase inhibition MK0457 in CML patients (0457-003) I NCT00111683 2005 Completed
43 Dasatinib MK0457 Aurora kinase inhibition Evaluation of efficacy and safety in patients with CML I NCT00500006 2007 Terminated